Volume 21, Number 6—June 2015
Cost-effectiveness of Chlamydia Vaccination Programs for Young Women
||Total cost†||QALYs lost||Incremental
|A) No screening, no vaccination||1,654||7,458||54,159,500||4,268||Referent||Referent||Referent|
|B) Screening 15–24-year-old persons
|75% efficacy lasting an average of 10 years|
|C) Screening 15–24-year-old persons and vaccinating 14-year-old persons||1,487||5,767||87,480,600||3,371||14,657,600‡||415‡||35,300|
|D) Screening 15–24-year-old persons,
vaccinating 14-year-old persons, and
catch-up vaccination of 15–24-year-old
|100% efficacy lasting for life|
*All outcomes (cumulative sequelae, quality-adjusted life-years [QALYs], and costs) have been discounted at an annual rate of 3%.
†Costs are in 2013 US dollars and rounded to the nearest hundred.
‡Incremental cost and QALYs when compared with strategy B (screening 15–24-year-old persons). Although this strategy was weakly dominated, we did not eliminate it because we wanted to show how the vaccine strategies compared with the status quo or existing strategy (B).